How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 10, 2012, Pages 1166-1172

  MacHado, Mariana V ^a   Coutinho, João ^a   Carepa, Fátima ^a   Costa, Adília ^a   Proença, Helena ^a   Cortez Pinto, Helena ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

adiponectin; ghrelin; leptin; nonalcoholic fatty liver

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GHRELIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADIPONECTIN; ADULT; ANALYSIS OF VARIANCE; BARIATRIC SURGERY; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; GHRELIN; HUMANS; HYPERTRIGLYCERIDEMIA; LEPTIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, MORBID; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84866335267     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32835609b0     Document Type: Article

References (61)

1. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37:1202-1209.
2. Yatagai T, Nagasaka S, Taniguchi A, Fukushima M, Nakamura T, Kuroe A, et al. Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 2003; 52:1274-1278. (Pubitemid 37351094)
3. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003; 285:E527-E533. (Pubitemid 37010830)
4. Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2010; 12:365-383.
5. Xu A, Wang Y, Keshal H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112:91-100. (Pubitemid 38056380)
6. Mendez-Sanchez N, Chavez-Tapia NC, Villa AR, Sanchez-Lara K, Zamora-Valdes D, Ramos MH, et al. Adiponectin as a protective factor in hepatic steatosis. World J Gastroenterol 2005; 11:1737-1741. (Pubitemid 40520759)
7. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Lasio R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005; 90:3498-3504. (Pubitemid 41014319)
8. Maeda K, Ishihara K, Miyake K, Kaji Y, Kawamitsu H, Fujii M, et al. Inverse correlation between serum adiponectin concentration and hepatic lipid content in Japanese with type 2 diabetes. Metabolism 2005; 54:775-780. (Pubitemid 40725327)
9. Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 2005; 152:113-118. (Pubitemid 40185459)
10. Targher G, Bertolini L, Rodella S, Zoppini G, Scala L, Zenari L, et al. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol 2006; 64:679-683. (Pubitemid 43775007)
11. Wong VW, Hui AY, Tsang SW, Chan JL, Am Tse, Chan KF, et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4:1154-1161. (Pubitemid 44311653)
12. Nazal L, Riquelme A, Solis N, Pizarro M, Escalona A, Burotto M, et al. Hypoadiponectinemia and its association with liver fibrosis in morbidly obese patients. Obes Surg 2010; 20:1400-1407.
13. Lucero D, Zago V, Lopez GI, Graffigna M, Fainboim H, Miksztowicz V, et al. Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome. Clin Chim Acta 2011; 412:143-147.
14. Kim SG, Kim HY, Seo JA, Lee KW, Oh HJ, Kim NH, et al. Relationship between serum adiponectin concentration, pulse wave velocity and nonalcoholic fatty liver disease. Eur J Endocrinol 2005; 152:225-231. (Pubitemid 40309569)
15. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27:412-421.
16. Aller R, de Luis DA, Fernandez L, Calle F, Velayos B, Olcoz JL, et al. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Dig Dis Sci 2008; 53:1088-1092. (Pubitemid 351379844)
17. Argentou M, Tiniakos DG, Karanikolas M, Melachrinou M, Makri MJ, Kittas C, et al. Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. Obes Surg 2009; 19:1313-1323.
18. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60:313-326.
19. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40:46-54. (Pubitemid 38868922)
20. Shimada M, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishima M. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol 2007; 102:1931-1938. (Pubitemid 47301507)
21. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008; 18:1430-1437.
22. Arvaniti VA, Thomopoulos KC, Tsamandas A, Makri M, Psyriogiannis A, Vafiadis G, et al. Serum adiponectin levels in different types of non alcoholic liver disease. Correlation with steatosis, necroinflammation and fibrosis. Acta Gastroenterol Belg 2008; 71:355-360.
23. Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009; 2009:831670.
24. Lee Y, Wang MY, Kakuma T, Wang ZW, Babcock E, McCorkle K, et al. Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J Biol Chem 2001; 276:5629-5635.
25. 2-dependant MAPK pathways. J Biol Chem 2004; 279:4292-4304. (Pubitemid 38199017)
26. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, et al. Leptin regulates proinflammatory immune responses. FASEB J 1998; 12:57-65. (Pubitemid 28060271)
27. Cohen BND, Rubinstein M. Modulation of insulin activities by leptin. Science 1996; 274:1185-1188. (Pubitemid 26389283)
28. Mark AL, Correia ML, Rahmouni K, Haynes WG. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens 2002; 20:1245-1250. (Pubitemid 34925659)
29. Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002; 36:413-419.
30. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004; 41:943-949. (Pubitemid 39575661)
31. Huang XD, Fan Y, Zhang H, Wang P, Yuan JP, Li MJ, et al. Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease. World J Gastroenterol 2008; 14:2888-2893.
32. Hindle AK, Edwards C, Mendonsa A, Rojkind M, McCaffrey T, Fu S, et al. Adiponectin but not leptin is involved in early hepatic disease in morbidly obese patients. Surg Endosc 2010; 24:1547-1551.
33. Chalasani N, Deeg MA, Persohn S, Crabb DW. Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98:1849-1855. (Pubitemid 36959169)
34. Musso G, Gambino R, Durazzo M, Biroli G, Carello M, Faga E, et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005; 42:1175-1183. (Pubitemid 43112685)
35. Dezaki K, Sone H, Yada T. Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol Ther 2008; 118:239-249.
36. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50:707-709. (Pubitemid 32242624)
37. Gauna C, Delhanty PJ, Hofland LJ, Janssen JA, Broglio F, Ross RJ, et al. Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab 2005; 90:1055-1060. (Pubitemid 40279233)
38. Higgins SC, Gueorguiev M, Korbonits M. Ghrelin, the peripheral hunger hormone. Ann Med 2007; 39:116-136. (Pubitemid 46598179)
39. Dixit VD, Taub DD. Ghrelin and immunity: a young player in an old field. Exp Gerontol 2005; 40:900-910. (Pubitemid 41540440)
40. Marchesini G, Pagotto U, Bugianesi E, de Lasio R, Manini R, Vanni E, et al. Low ghrelin concentrations in nonalcoholic fatty liver disease are related to insulin resistance. J Clin Endocrinol Metab 2003; 88:5674-5679. (Pubitemid 38033034)
41. Gutierrez-Grobe Y, Villalobos-Blasquez I, Sanchez-Lara K, Villa AR, Ponciano-Rodriguez G, Ramos MH, et al. High ghrelin and obestatin levels and low risk of developing fatty liver. Ann Hepatol 2010; 9:52-57.
42. Yalniz M, Bahcecioglu IH, Ataseven H, Ustundag B, Ilhan F, Poyrazoglu OK, et al. Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis. Mediators Inflamm 2006; 2006:34295.
43. Uribe M, Zamora-Valdes D, Moreno-Portillo M, Bermejo-Martinez L, Pichardo-Bahena R, Baptosta-Gonzalez HA, et al. Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease. Ann Hepatol 2008; 7:67-71. (Pubitemid 351468540)
44. Estep M, Abawi M, Jarrar M, Wang L, Stepanova M, Elariny H, et al. Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease. Obes Surg 2011; 21:1750-1757.
45. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr 1992; 55:615S-619S.
46. Group NHBPEPW. Report on primary prevention of hypertension. Arch Intern Med 1993; 153:325-334.
47. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419. (Pubitemid 15018832)
48. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26:3160-3167. (Pubitemid 37339514)
49. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
50. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313-1321. (Pubitemid 40770284)
51. Musso G, Gambino R, Biroli G, Carello M, Faga E, Pacini G, et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2005; 100:2438-2446.
52. Kakuma T, Lee Y, Higa M, Wang Z, Pan W, Shimomura I, et al. Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc Natl Acad Sci USA 2000; 97:8536-8541. (Pubitemid 30639708)
53. Friedman JM. Leptin, leptin receptors and the control of body weight. Eur J Med Res 1997; 2:7-13.
54. Cortez-Pinto H, Camilo ME, Baptista A, Oliveira AG, Moura MC. Nonalcoholic fatty liver-another feature of the metabolic syndrome? Clin Nutr 1999; 6:353-358. (Pubitemid 30032243)
55. Okamoto Y, Folco EJ, Minami M, Wara AK, Feinberg MW, Sukhova GK, et al. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res 2008; 102:218-225. (Pubitemid 351651126)
56. Rodriguez L, Graniel J, Ortiz R. Effect of leptin on activation and cytokine synthesis in peripheral blood lymphocytes of malnourished infected children. Clin Exp Immunol 2007; 148:478-485. (Pubitemid 46701024)
57. Chalasani N, Crabb DW, Cummings OW, Kwo PY, Asghar A, Pandya PK, et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol 2003; 98:2771-2776. (Pubitemid 38020122)
58. Krawczyk K, Szczesniak P, Kumor A, Jasinska A, Omulecka A, Pietruczuk M, et al. Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH). J Physiol Pharmacol 2009; 60 (Suppl 3):71-75.
59. Saxena NK, Titus MA, Ding X, Floyd J, Srinivasan S, Sitaraman SV, et al. Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. FASEB J 2004; 18:1612-1614. (Pubitemid 39561650)
60. Padoin AV, Mottin CC, Moretto M, Berleze D, Kupski C, Glock L, et al. A comparison of wedge and needle hepatic biopsy in open bariatric surgery. Obes Surg 2006; 16:178-182.
61. Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, et al. Diagnostic value of biochemical markers (Nash Test) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6:34.